Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.

Zhiwei ChenYuting WangTaiyu HeHu LiLing AoQingbo PanYingzhi ZhouQian ZhuDejuan XiangGaoli ZhangNing LingMin ChenPeng HuMingli PengDachuan CaiDazhi ZhangHong Ren

Published in: Journal of clinical and translational hepatology (2023)

The well tolerability and enhanced humoral immune response of inactivated vaccine supports an additional booster vaccination in AILD patients without immunosuppressants.

Keyphrases

immune response
sars cov
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
multiple sclerosis
prognostic factors
peritoneal dialysis
randomized controlled trial
dendritic cells
open label
clinical trial